{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T13:28:41Z","timestamp":1692538121940},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s00393-007-0176-2","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T19:20:03Z","timestamp":1179948003000},"page":"297-303","source":"Crossref","is-referenced-by-count":3,"title":["Zytokine","Cytokines"],"prefix":"10.1007","volume":"66","author":[{"given":"M.","family":"Feuchtenberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kneitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,12]]},"reference":[{"key":"176_CR1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","volume":"2","author":"Brennan","year":"1989","unstructured":"Brennan FM, Chantry D, Jackson A et al. (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244\u2013247","journal-title":"Lancet"},{"key":"176_CR2","first-page":"225","volume":"6","author":"Butler","year":"1995","unstructured":"Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6: 225\u2013230","journal-title":"Eur Cytokine Netw"},{"key":"176_CR3","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/eji.1830211039","volume":"21","author":"Haworth","year":"1991","unstructured":"Haworth C, Brennan FM, Chantry D et al. (1991) Expression of granulocyte\u2013macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21: 2575\u20132579","journal-title":"Eur J Immunol"},{"key":"176_CR4","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1084\/jem.179.5.1517","volume":"179","author":"Katsikis","year":"1994","unstructured":"Katsikis PD, Chu CQ, Brennan FM et al. (1994) Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 179: 1517\u20131527","journal-title":"J Exp Med"},{"key":"176_CR5","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1084\/jem.168.5.1573","volume":"168","author":"Firestein","year":"1988","unstructured":"Firestein GS, Xu WD, Townsend K et al. (1988) Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 168: 1573\u20131586","journal-title":"J Exp Med"},{"key":"176_CR6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.4049\/jimmunol.154.3.1432","volume":"154","author":"Chomarat","year":"1995","unstructured":"Chomarat P, Vannier E, Dechanet J et al. (1995) Balance of IL-1 receptor antagonist\/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 154: 1432\u20131439","journal-title":"J Immunol"},{"key":"176_CR7","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/eji.1830241119","volume":"24","author":"Joyce","year":"1994","unstructured":"Joyce DA, Gibbons DP, Green P et al. (1994) Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 24: 2699\u20132705","journal-title":"Eur J Immunol"},{"key":"176_CR8","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/1529-0131(199808)41:8<1388::AID-ART7>3.0.CO;2-F","volume":"41","author":"Hermann","year":"1998","unstructured":"Hermann JA, HallMA,Maini RN et al. (1998) Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 41: 1388\u20131397","journal-title":"Arthritis Rheum"},{"key":"176_CR9","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.4049\/jimmunol.165.5.2755","volume":"165","author":"Woods","year":"2000","unstructured":"Woods JM, Katschke KJ Jr, Tokuhira M et al. (2000) Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. J Immunol 165: 2755\u20132763","journal-title":"J Immunol"},{"key":"176_CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397\u2013440","journal-title":"Annu Rev Immunol"},{"key":"176_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.tips.2004.02.011","volume":"25","author":"Vilcek","year":"2004","unstructured":"Vilcek J, Feldmann M (2004) Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 25: 201\u2013209","journal-title":"Trends Pharmacol Sci"},{"key":"176_CR12","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","volume":"9","author":"Feldmann","year":"2003","unstructured":"Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9: 1245\u20131250","journal-title":"Nat Med"},{"key":"176_CR13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098\u20131104","journal-title":"N Engl J Med"},{"key":"176_CR14","first-page":"2","volume":"2","author":"Scherer","year":"2004","unstructured":"Scherer H, Burmester G (2004) Practical issues surrounding the use of biological therapies in patients with rheumatic diseases. Int J Adv Rheumatol 2: 2\u20138","journal-title":"Int J Adv Rheumatol"},{"key":"176_CR15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.10939","volume":"48","author":"Ekstrom","year":"2003","unstructured":"Ekstrom K, Hjalgrim H, Brandt L et al. (2003) Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 48: 963\u2013970","journal-title":"Arthritis Rheum"},{"key":"176_CR16","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932\u20131939","journal-title":"Lancet"},{"key":"176_CR17","doi-asserted-by":"crossref","unstructured":"Weinblatt ME, Keystone EC, Furst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48: 35\u201345 (Erratum in: Arthritis Rheum 2003, 48: 855; Arthritis Rheum 2004, 22: 144)","DOI":"10.1002\/art.10697"},{"key":"176_CR18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130: 478\u2013486","journal-title":"Ann Intern Med"},{"key":"176_CR19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253\u2013259","journal-title":"N Engl J Med"},{"key":"176_CR20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"Klareskog","year":"2004","unstructured":"Klareskog L, Heijde D van der, Jager JP de et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675\u2013681","journal-title":"Lancet"},{"key":"176_CR21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.191.2.313","volume":"191","author":"Horai","year":"2000","unstructured":"Horai R, Saijo S, Tanioka H et al. (2000) Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191: 313\u2013320","journal-title":"J Exp Med"},{"key":"176_CR22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","volume":"46","author":"Cohen","year":"2002","unstructured":"Cohen S, Hurd E, Cush J et al. (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 614\u2013624","journal-title":"Arthritis Rheum"},{"key":"176_CR23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","volume":"2","author":"Nishimoto","year":"2006","unstructured":"Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2: 619\u2013626; Review","journal-title":"Nat Clin Pract Rheumatol"},{"key":"176_CR24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2004.04.003","volume":"4","author":"McInnes","year":"2004","unstructured":"McInnes IB, Gracie JA (2004) Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 4: 392\u2013397","journal-title":"Curr Opin Pharmacol"},{"key":"176_CR25","first-page":"S241","volume":"50","author":"McInnes","year":"2004","unstructured":"McInnes I, Martin R, Zimmerman-Gorska I et al. (2004) Safety and efficacy of human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double blind, placebo-controlled trial. Arthritis Rheum 50 (Suppl): S241","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-007-0176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-007-0176-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-007-0176-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T23:27:14Z","timestamp":1683847634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-007-0176-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["176"],"URL":"https:\/\/doi.org\/10.1007\/s00393-007-0176-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}